Olanzapine and Chronic kidney disease - a phase IV clinical study of FDA data

Summary:

Chronic kidney disease is found among people who take Olanzapine, especially for people who are male, 50-59 old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Olanzapine and have Chronic kidney disease. It is created by eHealthMe based on reports of 54,854 people who have side effects when taking Olanzapine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

54,854 people reported to have side effects when taking Olanzapine.
Among them, 200 people (0.36%) have Chronic kidney disease.

What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 55,461 Olanzapine users for its effectiveness, alternative drugs and more.

What is Chronic kidney disease?

Chronic kidney disease is found to be associated with 2,517 drugs and 1,219 conditions by eHealthMe.

Number of Olanzapine and Chronic kidney disease reports submitted per year:

Could Olanzapine cause Chronic kidney disease?

* Approximation only. Some reports may have incomplete information.

Do you take Olanzapine and have Chronic kidney disease?

Check whether Chronic kidney disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .

Related studies

How severe was Chronic kidney disease and when was it recovered:

Chronic kidney disease in Olanzapine

Expand to all the drugs that have ingredients of olanzapine:

Chronic kidney disease and drugs with ingredients of olanzapine (311 reports)

Alternative drugs to, pros and cons of Olanzapine:

Olanzapine (55,461 reports)

Common Olanzapine side effects:

Drug ineffective: 4,209 reports
Agitation (state of anxiety or nervous excitement): 2,324 reports
Weight increased: 2,317 reports
Drowsiness: 2,274 reports
Fatigue (feeling of tiredness): 2,059 reports
Stress and anxiety: 1,925 reports

Browse all side effects of Olanzapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Chronic kidney disease treatments and more:

Chronic kidney disease (132,072 reports)

COVID vaccines that are related to Chronic kidney disease:

Common drugs associated with Chronic kidney disease:

All the drugs that are associated with Chronic kidney disease:

Chronic kidney disease (2,517 drugs)

Common conditions associated with Chronic kidney disease:

Gastroesophageal reflux disease: 33,556 reports
Hiv infection: 19,390 reports
Pain: 12,003 reports
High blood pressure: 11,782 reports
High blood cholesterol: 9,323 reports

All the conditions that are associated with Chronic kidney disease:

Chronic kidney disease (1,219 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olanzapine (the active ingredients of Olanzapine) and Olanzapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.